These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 29414118)

  • 1. The structured ambivalence of cannabis control in England & Wales.
    Brewster D
    Int J Drug Policy; 2018 Mar; 53():125-132. PubMed ID: 29414118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug policy reform and the reclassification of cannabis in England and Wales: A cautionary tale.
    Shiner M
    Int J Drug Policy; 2015 Jul; 26(7):696-704. PubMed ID: 25959525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The great cannabis classification debacle: what are the likely consequences for policing cannabis possession offences in England and Wales?
    Turnbull PJ
    Drug Alcohol Rev; 2009 Mar; 28(2):202-9. PubMed ID: 19320707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug Policy Governance in the UK: lessons from changes to and debates concerning the classification of cannabis under the 1971 Misuse of Drugs Act.
    Monaghan M
    Int J Drug Policy; 2014 Sep; 25(5):1025-30. PubMed ID: 24635973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabis legal debacle.
    de Kock M
    S Afr Med J; 2011 May; 101(5):284. PubMed ID: 21837862
    [No Abstract]   [Full Text] [Related]  

  • 6. Creating the cannabis user: a post-structuralist analysis of the re-classification of cannabis in the United Kingdom (2004-2005).
    Acevedo B
    Int J Drug Policy; 2007 May; 18(3):177-86. PubMed ID: 17689364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using the Advocacy Coalition Framework and Multiple Streams policy theories to examine the role of evidence, research and other types of knowledge in drug policy.
    Ritter A; Hughes CE; Lancaster K; Hoppe R
    Addiction; 2018 Aug; 113(8):1539-1547. PubMed ID: 29664153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Propagating the Haze? Community and professional perceptions of cannabis cultivation and the impacts of prohibition.
    Beckett Wilson H; Taylor S; Barrett G; Jamieson J; Grindrod L
    Int J Drug Policy; 2017 Oct; 48():72-80. PubMed ID: 28810157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabis policy reforms in the Americas: a comparative analysis of Colorado, Washington, and Uruguay.
    Pardo B
    Int J Drug Policy; 2014 Jul; 25(4):727-35. PubMed ID: 24970383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Legalization of medical marijuana (Cannabis).
    Porche DJ
    Am J Mens Health; 2013 Nov; 7(6):449. PubMed ID: 24027206
    [No Abstract]   [Full Text] [Related]  

  • 11. A tale of CIN--the Cannabis infringement notice scheme in Western Australia.
    Lenton S; Allsop S
    Addiction; 2010 May; 105(5):808-16. PubMed ID: 20331566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CMA position against separate regulations for medical cannabis draws ire and insults.
    Owens B
    CMAJ; 2018 May; 190(18):E574-E575. PubMed ID: 29735538
    [No Abstract]   [Full Text] [Related]  

  • 13. Cannabis policy: issues and options.
    Abel S; Casswell S
    N Z Med J; 1998 Sep; 111(1074):367-70. PubMed ID: 11039824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Health Policy Process in Vietnam: Going Beyond Kingdon's Multiple Streams TheoryComment on "Shaping the Health Policy Agenda: The Case of Safe Motherhood Policy in Vietnam".
    Kane S
    Int J Health Policy Manag; 2016 Jul; 5(7):435-437. PubMed ID: 27694671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attitudes of cannabis growers to regulation of cannabis cultivation under a non-prohibition cannabis model.
    Lenton S; Frank VA; Barratt MJ; Dahl HV; Potter GR
    Int J Drug Policy; 2015 Mar; 26(3):257-66. PubMed ID: 25181993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The three betrayals of the medical cannabis growing activist: From multiple victimhood to reconstruction, redemption and activism.
    Klein A; Potter GR
    Int J Drug Policy; 2018 Mar; 53():65-72. PubMed ID: 29287224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rhetorical and regulatory boundary-work: The case of medical cannabis policy-making in Israel.
    Zarhin D; Negev M; Vulfsons S; Sznitman SR
    Soc Sci Med; 2018 Nov; 217():1-9. PubMed ID: 30278412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The burgeoning recognition and accommodation of the social supply of drugs in international criminal justice systems: An eleven-nation comparative overview.
    Coomber R; Moyle L; Belackova V; Decorte T; Hakkarainen P; Hathaway A; Laidler KJ; Lenton S; Murphy S; Scott J; Stefunkova M; van de Ven K; Vlaemynck M; Werse B
    Int J Drug Policy; 2018 Aug; 58():93-103. PubMed ID: 29890504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Production, perceptions, and punishment: restrictive deterrence in the context of cannabis cultivation.
    Nguyen H; Malm A; Bouchard M
    Int J Drug Policy; 2015 Mar; 26(3):267-76. PubMed ID: 25223245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical use of cannabis in Australia: "medical necessity" defences under current Australian law and avenues for reform.
    Martin C
    J Law Med; 2014 Jun; 21(4):875-99. PubMed ID: 25087368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.